文献速递消化系统肿瘤妇科肿瘤

腹膜转移的当代管理:从治疗无效的冰冷过去到温暖现在与光明未来

The contemporary management of peritoneal metastasis: A journey from the cold past of treatment futility to a warm present and a bright future.
PubMed 文献 · CA Cancer J Clin · 2022-08-15

本文综述了腹膜转移(PM)的当代管理策略,涵盖阑尾癌、结直肠癌、间皮瘤和胃癌等高发肿瘤,并探讨了在晚期卵巢癌中细胞减灭术(CRS)联合全身治疗基础上加入腹腔热灌注化疗(HIPEC)的新兴作用及PARP维持治疗的最新临床试验。文章还讨论了精准医学技术在PM管理中的潜在价值。

要点

  • 腹膜转移常见症状,多模式治疗(全身治疗、CRS、HIPEC)已改善疗效。
  • 阑尾癌、结直肠癌、间皮瘤和胃癌是PM高发肿瘤,需综合管理。
  • 晚期卵巢癌中CRS联合全身治疗基础上可考虑加入HIPEC。

核心结论

  • 全身治疗优化、CRS改进及HIPEC与CRS联合的严谨研究,使PM多模式治疗更有效。

研究设计与样本

  • 文献综述,未报告系统检索策略。

主要发现

  • 早期化疗和不完全手术仅暂时缓解症状,持久控制罕见。
  • 持续开发更好的全身治疗组合、优化CRS及研究区域治疗(HIPEC)联合CRS,产生了更有效的多模式治疗选择。
  • 在晚期卵巢癌中,探索了在CRS和全身治疗范式上加入HIPEC的新兴作用。
  • 近期临床试验确定了PARP维持治疗在PM中的疗效。

临床怎么用

  • 对于阑尾癌、结直肠癌、间皮瘤和胃癌等高发PM肿瘤,当代管理采用多模式治疗。
  • 晚期卵巢癌中,在CRS和全身治疗基础上可考虑加入HIPEC(作者综述)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peritoneal metastasis (PM) is often regarded as a less frequent pattern of spread; however, collectively across all spectra of primary tumors, the consequences of PM impact a large population of patients annually. Unlike other modes of metastasis, symptoms at presentation or during the treatment course are common, representing an additional challenge in the management of PM. Early efforts with chemotherapy and incomplete surgical interventions transiently improved symptoms, but durable symptom control and survival extension were rare, which established a perspective of treatment futility for PM through most of the 20th century. Notably, the continued development of better systemic therapy combinations, optimization of cytoreductive surgery (CRS), and rigorous investigation of combining regional therapy-specifically hyperthermic intraperitoneal chemotherapy-with CRS, have resulted in more effective multimodal treatment options for patients with PM. In this article, the authors provide a comprehensive review of the data establishing the contemporary approach for tumors with a high frequency of PM, including appendix, colorectal, mesothelioma, and gastric cancers. The authors also explore the emerging role of adding hyperthermic intraperitoneal chemotherapy to the well established paradigm of CRS and systemic therapy for advanced ovarian cancer, as well as the recent clinical trials identifying the efficacy of poly(adenosine diphosphate ribose) polymerase maintenance therapy. Finally, recent data are included that explore the role of precision medicine technology in PM management that, in the future, may help further improve patient selection, identify the best systemic therapy regimens, detect actionable mutations, and identify new targets for drug development.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Foster JM, Zhang C, Rehman S, et al. The contemporary management of peritoneal metastasis: A journey from the cold past of treatment futility to a warm present and a bright future. CA Cancer J Clin. 2022. PMID: 35969103. doi:10.3322/caac.21749

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。